Tuberc Respir Dis.  2009 Feb;66(2):93-97.

Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer

• Ban HJ
• Oh IJ
• Kim KS
• Ju JY
• Kwon YS
• Kim YI
• Lim SC
• Kim YC

Abstract

No abstract available.

Keyword

Belotecan; Camptothecin; Small cell lung carcinoma; Relapse

MeSH Terms

Camptothecin
Recurrence
Small Cell Lung Carcinoma
Camptothecin

Figure

• 

  Figure 1 Overall survival in responders. The figure showed better overall survival in responders with belotecan compared to in non-responders: mean survival time of non-responders was 186 days (95% CI; 67~305), while was 401 days in responders (95% CI; 234~568, p=0.07).

• 

  Figure 2 Progression free survival showed tendency of better survival in responders: median progression free survival of responders was 112 days in contrast to 61 days of non-responders (p=0.06).

Reference

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004. 54:8–29.

2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005. 366:1385–1396.

3. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003. 123:259S–271S.

4. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The european organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol. 1997. 15:2090–2096.

5. Rocha Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung Cancer. 2003. 40:229–236.

6. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer. 1989. 59:578–583.

7. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci. 2000. 922:324–325.

8. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999. 17:658–667.

9. Eckardt JR, Ardizzoni A, von Pawel J, Fields S. Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer. Proc Am Soc Clin Oncol. 1997. 15:1624a.

10. Jeong JH, Kim SH, Choi HJ, Shin SJ, Cho BC, Kuen IC, et al. Phase II trial of belotecan in patients with relapsed small-cell lung cancer after irinotecan-containing chemotherapy. Korean J Med. 2007. 73:S155.